Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Conatus Pharmaceutic (CNAT)

Conatus Pharmaceutic (CNAT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Histogen Announces Successful Completion of its Merger with Conatus Pharmaceuticals

Histogen Inc. (NASDAQ: HSTO), a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today the completion of its previously disclosed...

HSTO : 3.01 (-10.94%)
CNAT : 0.5560 (+0.18%)
Acute Kidney Injury Treatment Market Present And Upcoming Trends With COVID 19 Impact Study | Novartis AG, Pfizer Inc, Ipsen SA

MarketResearch.Biz published a new industry research report “Acute Kidney Injury Treatment Market” in its database. This is a latest report, including the present COVID-19 impact and future effect on...

CNAT : 0.5560 (+0.18%)
IPSEY : 21.7500 (+3.42%)
MRK : 78.72 (-1.08%)
NVS : 87.80 (-0.75%)
PFE : 34.03 (-1.39%)
TEVA : 11.21 (-2.69%)
VRX.TO : 30.80 (-3.33%)
Leading Independent Proxy Advisory Firms Recommend Conatus Pharmaceuticals Shareholders Vote in Favor of its Merger with Histogen and the Required Reverse Stock Split

Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that Institutional Shareholder Services Inc. (ISS) and Glass Lewis, two leading independent research and proxy advisory firms that provide institutional...

CNAT : 0.5560 (+0.18%)
Histogen Publishes Preclinical Data on its HST 004 Spinal Disc Program

Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today the publication of data on HST 004, its patented, naturally-derived...

CNAT : 0.5560 (+0.18%)
Histogen Receives US FDA IND Approval to Initiate Phase 1b/2a Trial of HST 001 in Androgenic Alopecia

Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today that the U.S. Food and Drug Administration (FDA) has approved...

CNAT : 0.5560 (+0.18%)
The Conatus Pharmaceuticals Special Meeting of Stockholders Seeking Approval for Proposed Merger with Histogen Inc. will Reconvene on May 21, 2020

Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today convened and adjourned its special meeting of stockholders in order to obtain a quorum and specific stockholder approvals required pursuant to the terms...

CNAT : 0.5560 (+0.18%)
Conatus: 1Q Earnings Snapshot

SAN DIEGO (AP) _ Conatus Pharmaceuticals Inc. (CNAT) on Friday reported a loss of $3.5 million in its first quarter.

CNAT : 0.5560 (+0.18%)
Conatus Pharmaceuticals Reports First Quarter 2020 Financial Results and Strategic Process Update

Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced financial results for the first quarter ended March 31, 2020 and provided an update on its strategic process.

CNAT : 0.5560 (+0.18%)
Histogen Announces Investigational Device Exemption Application for HST 002

Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today that it has submitted an Investigational Device Exemption...

CNAT : 0.5560 (+0.18%)
Histogen Publishes New Preclinical Data on its HST 003 Orthopedic Program

Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today the publication of data on its human extracellular matrix...

CNAT : 0.5560 (+0.18%)
Histogen Announces Investigational New Drug Application Amendment for HST 001

Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today that it has submitted an Investigational New Drug (IND)...

CNAT : 0.5560 (+0.18%)
Conatus: 4Q Earnings Snapshot

SAN DIEGO (AP) _ Conatus Pharmaceuticals Inc. (CNAT) on Wednesday reported a loss of $2.7 million in its fourth quarter.

CNAT : 0.5560 (+0.18%)
Conatus Pharmaceuticals Reports 2019 Financial Results and Strategic Process Update

Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced financial results for the fourth quarter and full year ended December 31, 2019, and provided an update on its strategic process.

CNAT : 0.5560 (+0.18%)
Global Acute Kidney Injury Treatment Market Provides An In-Depth Insight Of Sales Analysis| Pfizer Inc, Ipsen SA and Novartis AG

Global Acute Kidney Injury Treatment Market (Revenue and Volume), Type, Application, End-User, and Regional Analysis, Import-Export Analysis, Industry Analysis, Premium Insights, Intellectual Property...

CNAT : 0.5560 (+0.18%)
IPSEY : 21.7500 (+3.42%)
MRK : 78.72 (-1.08%)
NVS : 87.80 (-0.75%)
PFE : 34.03 (-1.39%)
TEVA : 11.21 (-2.69%)
VRX.TO : 30.80 (-3.33%)
Histogen to Present at BIO CEO & Investor Conference

Histogen Inc., a regenerative medicine company with a unique biological platform that replaces and regenerates tissues in the body, announced today that it will be featured as a presenting company at the...

CNAT : 0.5560 (+0.18%)
Histogen and Allergan Expand Cell Conditioned Media (CCM) Skin Care Partnership

Histogen Inc., a regenerative medicine company with a unique biological platform that replaces and regenerates tissues in the body, today announced it has expanded its partnership with leading global biopharmaceutical...

AGN : 193.02 (+0.02%)
CNAT : 0.5560 (+0.18%)
Conatus Pharmaceuticals and Histogen Enter into Definitive Merger Agreement

Proposed Merger Creates Regenerative Medicine Company with Three Clinical-stage Product Candidates and Combined Company Capitalization Expected to Support Operations into 2021

CNAT : 0.5560 (+0.18%)
Intercept (ICPT) Gains 7.5% YTD on Progress in NASH Space

Intercept (ICPT) stock gains as it becomes the forerunner in the NASH drug race.

NVS : 87.80 (-0.75%)
CNAT : 0.5560 (+0.18%)
ICPT : 45.37 (-1.58%)
GILD : 76.42 (-0.44%)
NASH Scorecard Year to Date: The Winners and the Losers

NASH sees a highly rewarding market with candidates of blockbuster potential. Let us take a look at the hits and misses in this space so far this year.

AGN : 193.02 (+0.02%)
CNAT : 0.5560 (+0.18%)
ICPT : 45.37 (-1.58%)
GLMD : 4.78 (-0.62%)
CBAY : 3.44 (+1.78%)
MDGL : 108.47 (-0.82%)
Acute Kidney Injury Treatment Market Research Report on Revenue, Share, Volume and Size Outlook 2019-2028

CNAT : 0.5560 (+0.18%)
IPSEY : 21.7500 (+3.42%)
MRK : 78.72 (-1.08%)
NVS : 87.80 (-0.75%)
PFE : 34.03 (-1.39%)
VRX.TO : 30.80 (-3.33%)

Van Meerten Stock Picks

My 5 Favorite Mid Caps
Summary 100% technical buy signals with current momentum.
CRUS +0.61 , SEDG -2.31 , THC -0.85 , TER -1.79 , LITE -1.27
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar